CONMED CORPORATION Revenue from Contract with Customer, Excluding Assessed Tax
CONMED CORPORATION (CNMD) reported Revenue from Contract with Customer, Excluding Assessed Tax of $343.49 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-07-29
- CONMED CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $343.49M, a 0.33% increase year-over-year.
- CONMED CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $373.20M, a 7.88% increase year-over-year.
- CONMED CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $337.93M, a 6.70% increase year-over-year.
- CONMED CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2025-06-30 was $342.35M, a 3.09% increase year-over-year.
- CONMED CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2025 was $1.37B, a 5.18% increase from fiscal 2024.
- CONMED CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2024 was $1.31B, a 5.00% increase from fiscal 2023.
- CONMED CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2023 was $1.24B, a 19.06% increase from fiscal 2022.
- CONMED CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2022 was $1.05B, a 3.45% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $343.49M 10-Q · filed 2026-07-29 | $660.53M 10-Q · filed 2026-07-29 | ||
| 2025-12-31 | $373.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $711.12M derived: sum of 2 quarters · filed 2026-02-17 | $1.05B derived: sum of 3 quarters · filed 2026-07-29 | $1.37B 10-K · filed 2026-02-17 |
| 2025-09-30 | $337.93M 10-Q · filed 2025-11-06 | $680.27M derived: sum of 2 quarters · filed 2026-07-29 | $1.00B 10-Q · filed 2025-11-06 | $1.35B derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $342.35M 10-Q · filed 2026-07-29 | $663.60M 10-Q · filed 2026-07-29 | $1.01B derived: sum of 3 quarters · filed 2026-07-29 | $1.33B derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $321.26M 10-Q · filed 2025-05-01 | $667.20M derived: sum of 2 quarters · filed 2026-02-17 | $983.90M derived: sum of 3 quarters · filed 2026-02-17 | $1.32B derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-12-31 | $345.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $662.64M derived: sum of 2 quarters · filed 2026-02-17 | $994.74M derived: sum of 3 quarters · filed 2026-02-17 | $1.31B 10-K · filed 2026-02-17 |
| 2024-09-30 | $316.70M 10-Q · filed 2025-11-06 | $648.80M derived: sum of 2 quarters · filed 2025-11-06 | $961.07M 10-Q · filed 2025-11-06 | $1.29B derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $332.10M 10-Q · filed 2025-07-31 | $644.37M 10-Q · filed 2025-07-31 | $971.41M derived: sum of 3 quarters · filed 2026-02-17 | $1.28B derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $312.27M 10-Q · filed 2025-05-01 | $639.32M derived: sum of 2 quarters · filed 2026-02-17 | $943.90M derived: sum of 3 quarters · filed 2026-02-17 | $1.26B derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $327.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $631.62M derived: sum of 2 quarters · filed 2026-02-17 | $949.27M derived: sum of 3 quarters · filed 2026-02-17 | $1.24B 10-K · filed 2026-02-17 |
| 2023-09-30 | $304.58M 10-Q · filed 2024-10-31 | $622.23M derived: sum of 2 quarters · filed 2024-10-31 | $917.70M 10-Q · filed 2024-10-31 | $1.17B derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | $317.65M 10-Q · filed 2024-08-01 | $613.12M 10-Q · filed 2024-08-01 | $863.99M derived: sum of 3 quarters · filed 2025-02-18 | $1.14B derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | $295.47M 10-Q · filed 2024-04-25 | $546.34M derived: sum of 2 quarters · filed 2025-02-18 | $821.42M derived: sum of 3 quarters · filed 2025-02-18 | $1.10B derived: sum of 4 quarters · filed 2025-02-18 |
| 2022-12-31 | $250.87M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $525.96M derived: sum of 2 quarters · filed 2025-02-18 | $803.14M derived: sum of 3 quarters · filed 2025-02-18 | $1.05B 10-K · filed 2025-02-18 |
| 2022-09-30 | $275.09M 10-Q · filed 2023-10-26 | $552.28M derived: sum of 2 quarters · filed 2023-10-26 | $794.61M 10-Q · filed 2023-10-26 | $1.07B derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $277.19M 10-Q · filed 2023-07-27 | $519.52M 10-Q · filed 2023-07-27 | $793.49M derived: sum of 3 quarters · filed 2024-02-28 | $1.04B derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $242.33M 10-Q · filed 2023-04-27 | $516.30M derived: sum of 2 quarters · filed 2024-02-28 | $765.12M derived: sum of 3 quarters · filed 2024-02-28 | $1.02B derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $273.97M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $522.80M derived: sum of 2 quarters · filed 2024-02-28 | $777.96M derived: sum of 3 quarters · filed 2024-02-28 | $1.01B 10-K · filed 2024-02-28 |
| 2021-09-30 | $248.83M 10-Q · filed 2022-10-27 | $503.99M derived: sum of 2 quarters · filed 2022-10-27 | $736.66M 10-Q · filed 2022-10-27 | $989.49M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $255.16M 10-Q · filed 2022-07-28 | $487.84M 10-Q · filed 2022-07-28 | $740.67M derived: sum of 3 quarters · filed 2023-02-21 | $978.50M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $232.68M 10-Q · filed 2022-05-05 | $485.50M derived: sum of 2 quarters · filed 2023-02-21 | $723.34M derived: sum of 3 quarters · filed 2023-02-21 | $881.13M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $252.83M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $490.66M derived: sum of 2 quarters · filed 2023-02-21 | $648.45M derived: sum of 3 quarters · filed 2023-02-21 | $862.46M 10-K · filed 2023-02-21 |
| 2020-09-30 | $237.84M 10-Q · filed 2021-10-28 | $395.62M derived: sum of 2 quarters · filed 2021-10-28 | $609.63M 10-Q · filed 2021-10-28 | $874.50M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | $157.78M 10-Q · filed 2021-07-29 | $371.80M 10-Q · filed 2021-07-29 | $636.66M derived: sum of 3 quarters · filed 2022-02-22 | $870.25M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | $214.01M 10-Q · filed 2021-04-29 | $478.88M derived: sum of 2 quarters · filed 2022-02-22 | $712.47M derived: sum of 3 quarters · filed 2022-02-22 | $950.73M derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | $264.87M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $498.45M derived: sum of 2 quarters · filed 2022-02-22 | $736.72M derived: sum of 3 quarters · filed 2022-02-22 | $955.10M 10-K · filed 2022-02-22 |
| 2019-09-30 | $233.59M 10-Q · filed 2020-10-29 | $471.85M derived: sum of 2 quarters · filed 2020-10-29 | $690.23M 10-Q · filed 2020-10-29 | $932.67M derived: sum of 4 quarters · filed 2021-02-22 |
| 2019-06-30 | $238.26M 10-Q · filed 2020-07-30 | $456.64M 10-Q · filed 2020-07-30 | $699.08M derived: sum of 3 quarters · filed 2021-02-22 | $901.39M derived: sum of 4 quarters · filed 2021-02-22 |
| 2019-03-31 | $218.38M 10-Q · filed 2020-04-30 | $460.82M derived: sum of 2 quarters · filed 2021-02-22 | $663.13M derived: sum of 3 quarters · filed 2021-02-22 | $875.95M derived: sum of 4 quarters · filed 2021-02-22 |
| 2018-12-31 | $242.44M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-22 | $444.75M derived: sum of 2 quarters · filed 2021-02-22 | $657.57M derived: sum of 3 quarters · filed 2021-02-22 | $859.63M 10-K · filed 2021-02-22 |
| 2018-09-30 | $202.31M 10-Q · filed 2019-10-31 | $415.13M derived: sum of 2 quarters · filed 2019-10-31 | $617.19M 10-Q · filed 2019-10-31 | $839.75M derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-06-30 | $212.82M 10-Q · filed 2019-08-01 | $414.88M 10-Q · filed 2019-08-01 | $637.44M derived: sum of 3 quarters · filed 2020-02-24 | $827.56M derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-03-31 | $202.06M 10-Q · filed 2019-04-26 | $424.62M derived: sum of 2 quarters · filed 2020-02-24 | $614.74M derived: sum of 3 quarters · filed 2020-02-24 | $811.89M derived: sum of 4 quarters · filed 2020-02-24 |
| 2017-12-31 | $222.56M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $412.67M derived: sum of 2 quarters · filed 2020-02-24 | $609.83M derived: sum of 3 quarters · filed 2020-02-24 | $796.39M 10-K · filed 2020-02-24 |
| 2017-09-30 | $190.12M 10-Q · filed 2018-11-02 | $387.27M derived: sum of 2 quarters · filed 2018-11-02 | $573.84M 10-Q · filed 2018-11-02 | |
| 2017-06-30 | $197.15M 10-Q · filed 2018-08-02 | $383.72M 10-Q · filed 2018-08-02 | ||
| 2017-03-31 | $186.57M 10-Q · filed 2018-04-26 | |||
| 2016-12-31 | $763.52M 10-K · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| BIOLIFE SOLUTIONS INC (BLFS) | United States | $1.887B | 23.80 |
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Neuraxis, INC (NRXS) | United States | $0.097B |